Lamisil Singeldos

Terbinafine, the active ingredient in Lamisil Singeldos, is an allylamine antifungal presented as a topical formulation for cutaneous use. It treats dermatophyte infections of the skin and nails in adults and children as directed by a healthcare professional.

GNH USA supplies Lamisil Singeldos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Products are shipped with appropriate documentation and temperature control where required, ensuring compliance with local regulations.

Terbinafine is indicated for the treatment of dermatophyte infections affecting the skin and nails. - Athlete's foot (tinea pedis): reduces fungal growth and relieves itching, scaling and redness. - Ringworm (tinea corporis): eliminates the causative fungus and promotes healing of skin lesions. - Jock itch (tinea cruris): clears infection and diminishes discomfort in the groin area. - Fungal nail infection (tinea unguium): improves nail appearance by inhibiting fungal proliferation.

Topical terbinafine may cause local and, rarely, systemic adverse reactions.

Common Side Effects: - Burning sensation at the site of application, usually mild and transient. - Itching or pruritus that may develop within the first few days of use. - Redness, erythema accompanied by slight swelling of the treated area. - Dryness, peeling or flaking of the skin where the cream is applied.

Serious or Rare Side Effects: - Severe allergic reactions such as angioedema, swelling of lips, tongue or throat. - Contact dermatitis presenting with blistering, intense itching and rash spreading beyond the application site. - Generalized skin eruptions including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Rare systemic hepatotoxicity manifested by jaundice, abdominal pain or abnormal liver tests.

When using Lamisil Singeldos, certain precautions should be observed to ensure safety and effectiveness. - Pregnancy: consult a healthcare professional before use, as safety data are limited. - Breastfeeding: discuss potential risks with a physician, as drug may pass into milk. - Extensive skin damage: avoid application on open wounds, burns or severe dermatitis. - Large surface area: limit use to recommended area; excessive coverage may increase systemic absorption. - Concomitant systemic antifungals: inform the prescriber to monitor for possible drug interactions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Terbinafine may interact with other medicines; awareness of significant interactions helps prevent adverse effects.

Major Interactions (Avoid): - Co‑administration with systemic azole antifungals (e.g., itraconazole) can increase risk of hepatotoxicity. - Use together with strong CYP2D6 inhibitors (e.g., fluoxetine) may raise terbinafine plasma levels. - Concurrent warfarin therapy may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Applying other topical agents (e.g., corticosteroids) may mask infection signs or increase irritation. - Use with other dermatologic preparations containing alcohol may cause local burning.